Patent Filed for Colon-Cancer-Detection Blood Test

“American Cancer Society statistics show that when colon cancer is detected in its early stages, more than 90 percent of patients will survive. If not detected until the later stages, fewer than 10 percent will survive. ColoMarker™ detects colon cancer in these early, highly curable stages,” said Kevin Jones, PhD, chief scientific officer of EDP.  

With the use of ColoMarker™ the number of people being screened would likely increase dramatically, leading to a decline in deaths due to colon cancer, according to EDP.

In pre-clinical trials, ColoMarker™ detected the early stages (I, II, and III) of colon cancer. In tests of 2,370 blood samples, ColoMarker™ showed an accuracy rate of >99 percent for detecting colon cancer in these early stages. “ColoMarker™ could lead to a radical shift in the way we detect colon cancer,” Jones said.

“The use of ColoMarker™ as a screening test could save tens of thousands of American lives every year and billions of dollars in healthcare costs,” he continued. EDP Biotech is now moving forward expeditiously to get ColoMarker™ through the Food and Drug Administration clearance process.”

EDP Biotech Corporation (EDP) is a medical device company focused on the development and sale of immunodiagnostic tests for humans and animals.